Randomized Comparison of the RePneu Lung Volume Reduction Coil (LVRC) to Standard of Care for the Treatment of Emphysema (RESET Study)
This study is ongoing, but not recruiting participants.
Sponsor:
PneumRx, Inc.
Information provided by (Responsible Party):
PneumRx, Inc.
ClinicalTrials.gov Identifier:
NCT01334307
First received: April 1, 2011
Last updated: March 24, 2013
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to demonstrate the safety and performance of the PneumRx, Inc. Lung Volume Reduction Coil (LVRC) in a population of patients with emphysema. The PneumRx, Inc. LVRC is used as a less invasive alternative to lung volume reduction surgery.
| Condition | Intervention | Phase |
|---|---|---|
|
Emphysema |
Device: Lung Volume Reduction Coil (LVRC) (PneumRx) Device: Control |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Randomized Controlled Trial Of RePneu (LVRC) Endobronchial Coils For The Treatment Of Severe Emphysema With Hyperinflation (RESET Study) |
Resource links provided by NLM:
Further study details as provided by PneumRx, Inc.:
Primary Outcome Measures:
- St. George's Respiratory Questionnaire (SGRQ) [ Time Frame: three month Follow-Up Visit ] [ Designated as safety issue: No ]The primary efficacy endpoint will be the difference between treatment and control groups in the change in St. George's Respiratory Questionnaire (SGRQ) from Baseline (Pre-Treatment Visit) to the three month Follow-Up Visit.
| Estimated Enrollment: | 41 |
| Study Start Date: | February 2010 |
| Estimated Study Completion Date: | September 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Lung Volume Reduction Coil (LVRC)
Lung Volume Reduction Coil (LVRC)
|
Device: Lung Volume Reduction Coil (LVRC) (PneumRx)
Lung Volume Reduction Coil (LVRC)
Other Name: LVRD
|
|
Placebo Comparator: Control
Standard of Care
|
Device: Control
Standard of Care
Other Name: LVRC Control treatment is Standard of Care
|
Eligibility| Ages Eligible for Study: | 35 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient greater than or equal to 35 years of age
- High resolution CT scan indicates unilateral or bilateral emphysema
- High resolution CT scan indicates homogeneous or heterogeneous emphysema
- Patient has post-bronchodilator FEV1 less than or equal to 45% predicted
- Total Lung Capacity greater than 100% predicted
- Patient has marked dyspnea scoring greater than or equal to 2 on mMRC scale of 0-4
- Patient has stopped smoking for a minimum of 8 weeks prior to entering the study
- Patient (and legal guardian if applicable) read, understood and signed the Informed Consent form
Exclusion Criteria:
- Patient has a change in FEV1 greater than 20% post-bronchodilator
- Patients DLCO less than 20% predicted
- Patient has a history of recurrent clinically significant respiratory infection
- Patient has uncontrolled pulmonary hypertension defined by right ventricular pressure greater than 50mm Hg and/or evidenced by echocardiogram
- Patient has an inability to walk greater than 140 meters (150 yards) in 6 minutes
- Patient has evidence of other disease that may compromise survival such as lung cancer, renal failure, etc
- Patient is pregnant or lactating
- Patient has an inability to tolerate bronchoscopy under heavy sedation or anesthesia
- Patient has clinically significant bronchiectasis
- Patient has giant bullae greater than 1/3 lung volume
- Patient has had previous LVR surgery, lung transplant or lobectomy
- Patient has been involved in other pulmonary drug studies with 30 days prior to this study
- Patient is taking greater than 20 mg prednisone (or similar steroid) daily
- Patient is on Plavix or has not been weaned off prior to procedure
- Patient has other disease that would interfere with completion of study, follow up assessments or that would adversely affect outcomes
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01334307
Locations
| United Kingdom | |
| Glasgow, United Kingdom | |
| Chelsea and Westminster Hospital | |
| London, United Kingdom | |
| Manchester, United Kingdom | |
Sponsors and Collaborators
PneumRx, Inc.
Investigators
| Principal Investigator: | Pallav Shah, MD | Chelsea and Westminster Hospital |
More Information
No publications provided
| Responsible Party: | PneumRx, Inc. |
| ClinicalTrials.gov Identifier: | NCT01334307 History of Changes |
| Other Study ID Numbers: | CLN0008 |
| Study First Received: | April 1, 2011 |
| Last Updated: | March 24, 2013 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Keywords provided by PneumRx, Inc.:
|
Emphysema RePneu |
Additional relevant MeSH terms:
|
Emphysema Pulmonary Emphysema Pathologic Processes Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 22, 2013